Miao Zhang1, Limin Liu1, Feng Zhi2, Panpan Niu1, Mengya Yang1, Xuemei Zhu3, Ying Diao3, Yanmei Li3, Jun Wang4, Ying Zhao5. 1. Department of Pathophysiology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou 215123, China. 2. Modern Medical Research Center, Third Affiliated Hospital of Soochow University, Changzhou 213003, China. 3. Institutes of Biology & Medical Sciences, Soochow University, Suzhou 215123, China. 4. Institutes of Biology & Medical Sciences, Soochow University, Suzhou 215123, China. Electronic address: jwang79@suda.edu.cn. 5. Department of Pathophysiology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou 215123, China. Electronic address: yzhao@suda.edu.cn.
Abstract
BACKGROUND AND AIMS: Clinical studies have demonstrated that serum semicarbazide-sensitive amine oxidase (SSAO) activities positively correlate with the progression of atherosclerosis. The aim of the present study is to investigate the effect of SSAO inactivation on the development of atherosclerosis. METHODS: Female LDLr knockout (KO) mice were given the Western-type diet for 6 and 9 weeks to induce the formation of early and advanced lesions, and semicarbazide (SCZ, 0.125%) was added into the drinking water to inactivate SSAO in vivo. RESULTS: Despite no impact on plasma total cholesterol levels, abrogation of SSAO by SCZ not only resulted in the enlargement of both early (1.5-fold, p = 0.0043) and advanced (1.8-fold, p = 0.0013) atherosclerotic lesions, but also led to reduced/increased lesion contents of macrophages/smooth muscle cells (SMCs) (macrophage: ∼0.74-fold, p = 0.0002(early)/0.0016(advanced); SMC: ∼1.55-fold, p = 0.0003(early)/0.0001(advanced)), respectively. Moreover, SSAO inactivation inhibited the migration of circulating monocytes into peripheral tissues and reduced the amount of circulating Ly6C(high) monocytes (0.7-fold, p = 0.0001), which may account for the reduced macrophage content in lesions. In contrast, the increased number of SMCs in lesions of SCZ-treated mice is attributed to an augmented synthetic vascular SMC phenotype switch as evidenced by the increased proliferation of SMCs and accumulation of collagens in vivo. CONCLUSION: SSAO inactivation by SCZ promotes the phenotypic switch of SMCs and the development of atherosclerosis. The enzymatic activity of SSAO may thus represent a potential target in the prevention and/or treatment of atherosclerosis.
BACKGROUND AND AIMS: Clinical studies have demonstrated that serum semicarbazide-sensitive amine oxidase (SSAO) activities positively correlate with the progression of atherosclerosis. The aim of the present study is to investigate the effect of SSAO inactivation on the development of atherosclerosis. METHODS: Female LDLr knockout (KO) mice were given the Western-type diet for 6 and 9 weeks to induce the formation of early and advanced lesions, and semicarbazide (SCZ, 0.125%) was added into the drinking water to inactivate SSAO in vivo. RESULTS: Despite no impact on plasma total cholesterol levels, abrogation of SSAO by SCZ not only resulted in the enlargement of both early (1.5-fold, p = 0.0043) and advanced (1.8-fold, p = 0.0013) atherosclerotic lesions, but also led to reduced/increased lesion contents of macrophages/smooth muscle cells (SMCs) (macrophage: ∼0.74-fold, p = 0.0002(early)/0.0016(advanced); SMC: ∼1.55-fold, p = 0.0003(early)/0.0001(advanced)), respectively. Moreover, SSAO inactivation inhibited the migration of circulating monocytes into peripheral tissues and reduced the amount of circulating Ly6C(high) monocytes (0.7-fold, p = 0.0001), which may account for the reduced macrophage content in lesions. In contrast, the increased number of SMCs in lesions of SCZ-treated mice is attributed to an augmented synthetic vascular SMC phenotype switch as evidenced by the increased proliferation of SMCs and accumulation of collagens in vivo. CONCLUSION:SSAO inactivation by SCZ promotes the phenotypic switch of SMCs and the development of atherosclerosis. The enzymatic activity of SSAO may thus represent a potential target in the prevention and/or treatment of atherosclerosis.
Authors: Johanna M U Silvola; Helena Virtanen; Riikka Siitonen; Sanna Hellberg; Heidi Liljenbäck; Olli Metsälä; Mia Ståhle; Tiina Saanijoki; Meeri Käkelä; Harri Hakovirta; Seppo Ylä-Herttuala; Pekka Saukko; Matti Jauhiainen; Tibor Z Veres; Sirpa Jalkanen; Juhani Knuuti; Antti Saraste; Anne Roivainen Journal: Sci Rep Date: 2016-10-12 Impact factor: 4.379
Authors: Anna Filip; Soraya Taleb; Rümeyza Bascetin; Mohammad Jahangiri; Matthieu Bardin; Cindy Lerognon; Bruno Fève; Patrick Lacolley; Sirpa Jalkanen; Nathalie Mercier Journal: Front Cardiovasc Med Date: 2022-09-13
Authors: Nathalie Mercier; Sven-Christian Pawelzik; John Pirault; Miguel Carracedo; Oscar Persson; Bastien Wollensack; Anders Franco-Cereceda; Magnus Bäck Journal: Oxid Med Cell Longev Date: 2020-01-14 Impact factor: 6.543